Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWong, Darren-
dc.contributor.authorMatini, Lawrence-
dc.contributor.authorKormilitzin, Andrey-
dc.contributor.authorKantschuster, Ramona-
dc.contributor.authorSimadibrata, Daniel Martin-
dc.contributor.authorLyden, Sara-
dc.contributor.authorWilson, Jean-
dc.contributor.authorBrain, Oliver A-
dc.contributor.authorPalmer, Rebecca-
dc.contributor.authorAmbrose, Tim-
dc.contributor.authorSatsangi, Jack-
dc.contributor.authorSouth, Matthew-
dc.contributor.authorGeddes, John-
dc.contributor.authorBodger, Keith-
dc.contributor.authorTravis, Simon P L-
dc.contributor.authorWalsh, Alissa-
dc.identifier.citationJournal of Crohn's & colitis 2022; online first: 22 Julyen
dc.description.abstractPatient reported outcome measures (PROMs) are key to documenting outcomes that matter most to patients and are increasingly important to commissioners of healthcare seeking value. We report the first series of the ICHOM Standard Set for Inflammatory Bowel Disease (IBD). Patients treated for ulcerative colitis (UC) or Crohn's disease (CD) in our centre were offered enrolment into the web-based TrueColours-IBD programme. Through this programme, email prompts linking to validated questionnaires were sent for symptoms, quality of life, and ICHOM IBD outcomes. The first 1,299 consecutive patients enrolled (779 UC, 520 CD) were studied with median 270 days of follow up (IQR 116-504). 671 (52%) were female, mean age 42 years (sd 16), mean BMI 26 (sd 5.3). 483 (37%) were using advanced therapies at registration. Median adherence to fortnightly quality of life reporting and quarterly outcomes was 100% [IQR48-100%] and 100% [IQR75-100%], respectively. In the previous 12 months, prednisolone use was reported by 229 (29%) patients with UC vs. 81 (16%) with CD, p<0.001: 202 (16%) for <3 months and 108 (8%) for >3 months. 174 (13%) patients reported an IBD-related intervention and 80 (6%) reported an unplanned hospital admission. There were high rates of fatigue (50%) and mood disturbance (23%). Outcomes reported by patients illustrate the scale of the therapeutic deficit in current care. Proof of principle is demonstrated that PROM data can be collected continuously with little burden on healthcare professionals. This may become a metric for quality improvement programmes, or to compare outcomes.en
dc.subjectInflammatory bowel diseaseen
dc.subjectpatient reported outcomesen
dc.titlePatient Reported Outcomes: the ICHOM Standard Set for inflammatory bowel disease in real life practice helps quantify deficits in current care.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Crohn's & colitisen
dc.identifier.affiliationDepartment of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia..en
dc.identifier.affiliationTranslational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust and NIHR Biomedical Research Centre, Oxford, United Kingdom..en
dc.identifier.affiliationDepartment of Psychiatry, University of Oxford, Oxford, United Kingdom..en
dc.identifier.affiliationFaculty of Medicine, Universitas Indonesia, Jakarta, Indonesia..en
dc.identifier.affiliationDepartment of Health Data Science, Institute of Population Health, University of Liverpool, United Kingdom..en
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.